The stock of Vir Biotechnology Inc (NASDAQ: VIR) has decreased by -0.79 when compared to last closing price of 10.17.Despite this, the company has seen a loss of -4.09% in its stock price over the last five trading days. InvestorPlace reported 2024-03-19 that Given the current risk-on sentiment, it is perhaps an ideal time for investors to scoop up some of the top biotech stocks. The stock market is booming, and with investors looking to take on more risk, a potential surge in biotech stocks seems likely.
Is It Worth Investing in Vir Biotechnology Inc (NASDAQ: VIR) Right Now?
The stock has a 36-month beta value of 0.41. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VIR is 87.99M, and at present, short sellers hold a 5.77% of that float. On March 22, 2024, the average trading volume of VIR was 1.11M shares.
VIR’s Market Performance
VIR stock saw a decrease of -4.09% in the past week, with a monthly decline of -0.20% and a quarterly a decrease of 0.60%. The volatility ratio for the week is 5.08%, and the volatility levels for the last 30 days are 5.32% for Vir Biotechnology Inc (VIR). The simple moving average for the past 20 days is -8.30% for VIR’s stock, with a -19.85% simple moving average for the past 200 days.
Analysts’ Opinion of VIR
Many brokerage firms have already submitted their reports for VIR stocks, with JP Morgan repeating the rating for VIR by listing it as a “Neutral.” The predicted price for VIR in the upcoming period, according to JP Morgan is $9 based on the research report published on January 29, 2024 of the current year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see VIR reach a price target of $14, previously predicting the price at $23. The rating they have provided for VIR stocks is “Neutral” according to the report published on September 08th, 2023.
JP Morgan gave a rating of “Overweight” to VIR, setting the target price at $34 in the report published on March 06th of the previous year.
VIR Trading at -1.02% from the 50-Day Moving Average
After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.28% of loss for the given period.
Volatility was left at 5.32%, however, over the last 30 days, the volatility rate increased by 5.08%, as shares sank -2.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.88% lower at present.
During the last 5 trading sessions, VIR fell by -4.09%, which changed the moving average for the period of 200-days by -62.18% in comparison to the 20-day moving average, which settled at $10.99. In addition, Vir Biotechnology Inc saw 0.30% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VIR starting from SCANGOS GEORGE A, who sale 17,722 shares at the price of $11.65 back on Feb 26 ’24. After this action, SCANGOS GEORGE A now owns 112,989 shares of Vir Biotechnology Inc, valued at $206,522 using the latest closing price.
Pang Phillip, the EVP & Chief Medical Officer of Vir Biotechnology Inc, sale 14,568 shares at $10.05 during a trade that took place back on Feb 22 ’24, which means that Pang Phillip is holding 250,111 shares at $146,344 based on the most recent closing price.
Stock Fundamentals for VIR
Current profitability levels for the company are sitting at:
- -14.19 for the present operating margin
- 0.84 for the gross margin
The net margin for Vir Biotechnology Inc stands at -13.18. The total capital return value is set at -0.37. Equity return is now at value -33.53, with -24.54 for asset returns.
Based on Vir Biotechnology Inc (VIR), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -6.25.
Currently, EBITDA for the company is -641.55 million with net debt to EBITDA at 0.2. When we switch over and look at the enterprise to sales, we see a ratio of 26.4. The receivables turnover for the company is 4.02for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.05.
Conclusion
To sum up, Vir Biotechnology Inc (VIR) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
